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Abstract
Aims Neuroendocrine activation is associated with poor outcome in heart failure (HF). The neuropeptide gastrin-releasing
peptide (GRP), derived from the precursor proGRP1-125 (proGRP), has recently been implicated in inﬂammation and wound
repair. We investigated the predictive value of proGRP on clinical outcomes in HF patients with reduced ejection fraction.
Methods and results The association between plasma proGRP (time-resolved immunoﬂuorometric assay) and the primary
endpoint of death from any cause or ﬁrst hospitalization for worsening of HF was evaluated using multivariable Cox propor-
tional hazard models in 1541 patients with systolic HF and mild to moderate anaemia, enrolled in the Reduction of Events by
Darbepoetin alfa in Heart Failure (RED-HF) trial. Median proGRP levels in the RED-HF cohort were markedly increased [95 ng/L
(25th, 75th percentile, 69–129 ng/L)] with 64% patients above the 80 ng/L reference limit. Baseline proGRP correlated with
estimated glomerular ﬁltration rate (r = 0.52), N terminal pro brain natriuretic peptide (r = 0.33), troponin T (r = 0.34), and
haemoglobin (r = 0.16) (all P < 0.001). The incidence outcome increased with increasing tertiles of baseline proGRP (primary
endpoint third tertile vs. the lowest tertile; hazard ratio 1.91; 95% conﬁdence interval 1.60–2.28, P < 0.001). However, these
associations were markedly attenuated and non-signiﬁcant in adjusted models. No interaction between baseline proGRP and
the effect of darbepoetin alfa treatment was detected. Moreover, no signiﬁcant association between changes in proGRP dur-
ing 6 month follow-up and outcome was observed.
Conclusions Pro-gastrin-releasing peptide is increased in patients with HF with reduced ejection fraction and anaemia, in
particular in patients with poor renal function. However, proGRP adds little as a prognostic marker on top of conventional
HF risk factors.
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Introduction
Neuroendocrine activation is a key feature in patients with
certain cancers and in heart failure (HF) and is an
established predictor of poor prognosis in both popula-
tions.1,2 Neuroendocrine tumours produce proteins such
as chromogranin A (CgA) that reﬂect neuroendocrine differ-
entiation in various cancers3 but are also associated with
severity and outcomes in HF.4 Conversely, neurohormones
such as natriuretic peptides, adrenomedullin, endothelin,
and copeptin are elevated in cancer patients and related
to all-cause mortality.5
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The neuropeptide gastrin-releasing peptide (GRP) is a
mammalian bombesin homologue,6 involved in a multitude
of physiological functions with a widespread distribution in
the body, particularly in neuroendocrine cells, stimulating
the release of other hormones including norepinephrine.7 Re-
cently, GRP has also been implicated in inﬂammation and
wound repair.8 While GRP is highly unstable in blood and dif-
ﬁcult to monitor, the pro-peptide pro-gastrin-releasing pep-
tide (proGRP) is stable with a long half-life. The circulating
levels of proGRP are frequently measured in the diagnostic
workup of patients with pulmonary tumours.9 In addition to
CgA, the ovarian cancer marker carbohydrate antigen 125
(CA-125) and the WAP four-disulﬁde core domain protein
HE4 have been shown to correlate with clinical severity and
adverse outcome in HF patients.4,10,11 Based on the role of
GRP in inﬂammation and tissue repair and ability to reﬂect
neuroendocrine activation, it is conceivable that proGRP also
could be regulated during HF, but this hypothesis has not
been studied.
To investigate the association between circulating
proGRP and HF, we ﬁrst evaluated circulating levels of
proGRP in a small well-characterized population of HF pa-
tients compared with matched controls. We then assessed
whether proGRP predicted clinical outcomes in 1588 pa-
tients with HF and anaemia, enrolled in the Reduction of
Events by Darbepoetin alfa in Heart Failure (RED-HF) trial.12
Based on its potential to reﬂect distinct pathophysiologic
mechanisms in HF such as neuroendocrine activation, ﬁbro-
sis, and inﬂammation, we hypothesized that proGRP could
represent a novel biomarker for adverse outcome in these
patients.
Materials and methods
Patients and study procedures
Cross-sectional cohort
One hundred and thirty-nine consecutive patients with
chronic HF with reduced ejection fraction (HFrEF) referred
to our tertiary hospital for evaluation were enrolled in the
study. Patients with acute coronary syndromes within the last
6 months or with signiﬁcant concomitant disease (e.g. malig-
nancies, autoimmune disorders, or liver or kidney failure)
were not included. The composite endpoint of all-cause mor-
tality and heart transplantation was used as the outcome var-
iable. The control group consisted of 32 sex-matched and
age-matched healthy individuals.
RED-HF cohort
The study design, as well as baseline characteristics and re-
sults of RED-HF trial (http://clinicaltrials.gov number:
NCT00358215), has been published.13,14 Patients were eligible
for the study if they had New York Heart Association (NYHA)
functional class II–IV HF, left ventricular ejection fraction
(LVEF) ≤ 40%, haemoglobin level 9.0 to 12.0 g/dL, and were re-
ceiving guideline-recommended HF therapy. Major exclusion
criteria included transferrin saturation of less than 15%, evi-
dence of bleeding or other correctable causes of anaemia, a
serum creatinine level more than 3 mg/dL (265 μmol/L), and
blood pressure more than 160/100 mmHg. Patients were ran-
domly assigned in a 1:1 ratio to receive either darbepoetin alfa
or placebo. The study drug was administered subcutaneously,
with doses adjusted to maintain a haemoglobin level of
13.0 g/dL. The primary predeﬁned outcome was a composite
of death from any cause or ﬁrst hospitalization for worsening
of HF. The pre-speciﬁed adjudicated secondary outcomes
were (i) the composite of death from cardiovascular (CV)
causes or ﬁrst hospitalization for worsening of HF, (ii) death
from any cause, and (iii) CV death.
Both studies complied with the Declaration of Helsinki
and were approved by the ethics committees of the partic-
ipating hospitals. All patients provided written informed
consent.
Biochemistry and blood sampling
Peripheral venous blood was drawn into pyrogen-free tubes
with EDTA as anticoagulant, and plasma was isolated and
stored at 80°C following centrifugation. The plasma from
the cross-sectional population has previously been thawed
once, while samples from RED-HF had not been thawed
previously. ProGRP was analysed by time-resolved
immunoﬂuorometric assay.9 N terminal pro brain natriuretic
peptide (NT-proBNP), C-reactive protein, and troponin T
(TnT) were assayed on a MODULAR platform (Roche Diag-
nostics, Basel, Switzerland). Both C-reactive protein and
TnT were measured by a high-sensitivity assay. Galectin-3
levels have been determined previously in the clinical HF
cohort and were determined by enzyme-linked immunosor-
bent assay (BG Medicine, Waltham, MA).15
Statistical analysis
Trends across tertiles of proGRP were tested using Kruskal–
Wallis H test, one-way ANOVA, or χ2 depending on distribu-
tion and variable type (i.e. categorical or continuous). For
comparing treatment effects on proGRP, the Mann–
Whitney U-test was used on change values, while Wilcoxon
matched pairs test was used to assess longitudinal changes
within groups. Stepwise linear regression was used to iden-
tify the most important predictors of proGRP. Kaplan–
Meier curves were constructed to visualize and evaluate
(log-rank test) differences in survival. A restricted cubic
spline analysis with three knots was undertaken on the pri-
mary outcome to assess linearity of risk. Survival analyses
ProGRP in heart failure 1053
ESC Heart Failure 2018; 5: 1052–1059
DOI: 10.1002/ehf2.12312
for RED-HF were performed using the Cox proportional haz-
ard regression models to estimate hazard ratios (HRs) and
95% conﬁdence intervals for the leukocyte markers in-
cluded as log-transformed continuous variables at baseline,
which included mainly clinical variables at Step 1 [age, gen-
der, NYHA class, hospitalization for HF within 6 months, log
serum creatinine, LVEF, aetiology, body mass index (BMI),
left bundle-branch block, history of atrial ﬁbrillation or ﬂut-
ter, and systolic blood pressure]. At Step 2, log-transformed
serum concentrations of TnT, NT-proBNP, and C-reactive
protein were included. Interaction between proGRP and
BMI on outcomes was assessed in a Cox proportional haz-
ard regression model including the proGRP, BMI, and their
interaction term.
For the analysis of changes in proGRP concentrations from
baseline to 6 month follow-up, a 15% relative change was
used as cut-off, which is consistent with other studies.16
Harrell’s C-statistic and net reclassiﬁcation improvement
were calculated to evaluate the prognostic usefulness of bio-
markers. A two-sided P-value < 0.05 was considered to be
signiﬁcant. All statistical analyses were performed with the
use of SAS software, version 9.2.
Results
Plasma pro-gastrin-releasing peptide levels in the
clinical heart failure cohort
Median plasma levels of proGRP were mildly elevated in 139
HF patients [mean age ± standard deviation 57 ± 11 years,
18% women, BMI 26.8 ± 5.7 kg/m2, NYHA class (II 27%, III
48%, and IV 25%), 48% ischaemic aetiology, LVEF 29 ± 11, es-
timated glomerular ﬁltration rate (eGFR) 76 ± 25 mL/min/
1.73m2] compared with 32 matched healthy controls (age
57 ± 11 years, 16% women): median 54 ng/L (25th, 75th per-
centile: 42, 75 ng/L) vs. 51 (38, 57) ng/L, P = 0.046, respec-
tively. A higher proportion of HF patients had proGRP levels
above the 80 ng/L reference limit compared with controls
(3% vs. 20%, P = 0.024), and only 6% of controls had levels
in the top tertile of HF patients (P = 0.002). Increased proGRP
levels were associated with clinical severity as evaluated by
NYHA (Figure 1A) with particularly high levels in NYHA IV
(P = 0.003 and P = 0.019 vs. controls and NYHA II, respec-
tively) but not with ischaemic aetiology (P = 0.24). ProGRP
showed a strong inverse correlation with eGFR (r = 0.60,
P < 0.001), positive correlation with galectin-3 (r = 0.49,
P < 0.001), modest positive correlation with NT-proBNP
(r = 0.39, P < 0.001) (Figure 1B), and poor and insigniﬁcant
correlation with LVEF (r = 0.16, P = 0.08) and C-reactive
protein (r = 0.13, P = 0.134). Kaplan–Meier analysis revealed
a signiﬁcant association with the composite of death/heart
transplantation (n = 47) when evaluated as tertiles (Figure 1C)
and according to the reference cut-off of 80 ng/L (i.e. above
or below 80 ng/L, P = 0.022).
Plasma pro-gastrin-releasing peptide in the
RED-HF cohort
Of the 2278 patients enrolled in the RED-HF study, measure-
ment of proGRP at baseline was available in 1541 (68%) sub-
jects. Table 1 shows the baseline demographic and clinical
characteristics according to tertiles of proGRP.Median proGRP
levels were markedly higher in the RED-HF cohort: 95
(69, 129) ng/L with 64% of patients having levels above the
80 ng/L reference limit. Elevated proGRP were associated with
several features indicating more severe HF such as NYHA class,
duration of disease, incidence of atrial ﬁbrillation/ﬂutter, poor
kidney function, higher TnT and NT-proBNP levels, and rele-
vant to this population, lower haemoglobin and transferrin
saturation. Similar to the clinical HF cohort, proGRPwas poorly
correlated with C-reactive protein (r = 0.05, P = 0.067). Step-
wise linear regression analyses revealed that the ﬁve strongest
predictors of proGRP were eGFR (B ± standard er-
ror = 0.03 ± 0.1), log NT-proBNP (B = 6.9 ± 2.1), creatinine
(B = 43 ± 6), male sex (B = 25 ± 4), and age
(B = 0.66 ± 0.16), all P < 0.001.
Association between baseline
pro-gastrin-releasing peptide levels and outcome
in RED-HF
During a median follow-up of 28 months (range 0.03–72.4
months), 784 patients reached a primary endpoint, 703 pa-
tients reached the composite of death from CV causes or ﬁrst
hospitalization for worsening of HF, while 637 patients died,
532 due to CV causes. The cubic spline analysis revealed a lin-
ear increase in the primary endpoint of RED-HF within the
range of ﬁrst and second tertile, followed by ﬂattening of
the curve around Tertile 3 (Figure 2A). Kaplan–Meier esti-
mates for the primary endpoint according to baseline tertiles
of proGRP are presented in Figure 2B showing lower risk in
Tertile 1 (≤77 ng/L), similar to the upper reference limit in
our laboratory (>80 ng/L), with a stepwise increase in risk
at higher tertiles (Figure 2B).
In unadjusted analyses, baseline proGRP by tertiles and as
a continuous variable was signiﬁcantly associated with all
endpoints with HRs ranging from 1.86 to 2.06 for Tertile 3
compared with Tertile 1 (all P < 0.001) (Table 2). In multivar-
iable analysis adjusting for pre-speciﬁed clinical variables
(i.e. age, gender, NYHA class, hospitalization for HF within
6 months, log serum creatinine, LVEF, aetiology, BMI, left
bundle-branch block, history of atrial ﬁbrillation or ﬂutter,
and systolic blood pressure), the associations with outcome
were markedly attenuated but remained signiﬁcant for the
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primary endpoint and mortality when evaluated as a contin-
uous variable and tertiles (Table 2). When NT-proBNP, TnT,
and C-reactive protein were added to the multivariable
models, however, the signiﬁcance of proGRP was further at-
tenuated and was no longer signiﬁcant for any outcome
with HRs around 1 (Step 2, Table 2).
As proGRP was inversely associated with BMI, we also
assessed if there was an interaction between BMI and
proGRP for the risk of adverse outcome (Table 3). This analy-
sis revealed an association between low BMI and poor prog-
nosis for the mortality outcomes but not the composite
outcomes. However, no interaction between BMI and proGRP
was detected.
No association between change in proGRP (i.e. decrease:
<15%; no change: 15–15%; increase: >15%) and any out-
come was observed in univariate analysis (P-values between
0.16 and 0.28).
Effect of darbepoetin alpha on
pro-gastrin-releasing peptide levels and clinical
outcomes
Plasma proGRP levels were similar at baseline in the pla-
cebo and darbepoetin alpha treatment groups (mean ± stan-
dard deviation 105 ± 55 ng/L vs. 110 ± 79 ng/L, P = 0.163,
respectively). At 6 months, there was no clear effect of
darbepoetin alpha therapy on proGRP levels (6 month
levels 105 ± 56 and 108 ± 86 ng/L, P = 0.724, in placebo
and darbepoetin alpha groups, respectively), although a mi-
nor difference in the change in proGRP between the groups
was noted (3 ± 33 vs. 1 ± 32 ng/L, P = 0.033, placebo and
darbepoetin alpha, respectively). No interaction between
baseline proGRP levels and darbepoetin alpha on any out-
come was observed (P-values 0.19–0.29 in unadjusted
analyses).
Figure 1 Circulating levels of pro-gastrin-releasing peptide (proGRP) in 139 patients with heart failure according to (A) New York Heart Association
(NYHA) class and compared with age-matched and sex-matched healthy controls (CTR, n = 32); (B) correlation with estimated glomerular ﬁltration rate
(eGFR), N terminal pro brain natriuretic peptide (NT-proBNP), and galectin-3 levels; and (C) cumulative incidence of a composite endpoint consisting
of all-cause mortality and heart transplantation (n = 47) shown as Kaplan–Meier curves according to tertiles of proGRP (T1: ≤46; T2: 47–65; T3:
>65 ng/L).
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Table 1 Characteristics of patients from the RED-HF trial according to proGRP tertiles at baseline
Characteristic T1, n = 515 T2, n = 513 T3, n = 513 P-value
ProGRP (ng/L) ≤77 78–115 >115
Age, years 66 ± 12 70 ± 11 73 ± 11 <0.001
Female sex 49 39 42 0.006
Race (White/Black) 63/13 65/10 72/7
BMI (SD), kg/m2 27.9 ± 5.7 27.1 ± 5.7 26.4 ± 5.5 <0.001
NYHA (III or IV) 65 65 71 0.039
Ischaemic HF 65 73 76 <0.001
Duration HF, years 4.9 ± 5.0 5.5 ± 5.5 5.8 ± 5.7 0.009
LVEF, % 30.6 ± 6.6 30.2 ± 6.6 29.9 ± 7.3 0.429
Medical history
Hypertension 77 72 73 0.240
Diabetes 42 49 44 0.620
Atrial ﬁbrillation or ﬂutter 25 34 37 <0.001
Hospitalization WHF 33 37 39 0.168
Medication
ACE-Inhibitors or ARB 93 90 88 0.016
Beta-blocker 85 86 85 0.881
Diuretic 88 92 94 0.001
Systolic BP 123 ± 17 120 ± 18 118 ± 19 <0.001
Heart rate, b.p.m. 73 ± 11 72 ± 11 72 ± 11 0.117
Biochemistry
Creatinine, mg/dL 1.2 ± 0.4 1.5 ± 0.5 1.8 ± 0.6 <0.001
eGFR, mL/min/1.73m2 64 ± 23 49 ± 19 38 ± 14 <0.001
Haemoglobin, g/dL 11.2 ± 0.7 11.0 ± 0.7 10.9 ± 0.7 <0.001
Transferrin saturation, % 27.9 ± 11.2 26.9 ± 10.6 26.4 ± 11.0 0.010
Platelets 241 ± 76 232 ± 80 222 ± 76 <0.001
WBC 6.8 ± 2.3 6.8 ± 2.3 6.7 ± 1.9 0.811
hsCRP, mg/dL 1.0 (0.7, 1.3) 1.0 (0.7, 1.5) 1.1 (0.7, 1.5) 0.188
NT-proBNP, pmol/L 0.7 (0.3, 1.3) 1.1 (0.7, 2.0) 1.5 (0.8, 2.7) <0.001
hsTnT, ng/mL 0.6 (0.3, 1.2) 1.1 (0.6, 2.0) 1.5 (0.8, 2.7) <0.001
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glo-
merular ﬁltration rate; HF, heart failure; hsCRP, high-sensitivity C-reactive protein; hsTnT, high-sensitive troponin; LVEF, left ventricular
ejection fraction; proGRP, pro-gastrin-releasing peptide; NT-proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart As-
sociation; SD, standard deviation; WBC, white blood cell; WHF, worsening heart failure.
Patient characteristics are given as mean ± SD for continuous variables and % of cases for categorical variables.
Figure 2 Association between baseline pro-gastrin-releasing peptide (proGRP) levels and the primary endpoint (n = 784) in the RED-HF cohort
(n = 1541) during the whole study (mean follow-up: 28 months; range: 0.03–72.4 months) expressed as (A) restricted cubic spline with tertile cut-offs
at enrolment shown as lines and (B) Kaplan–Meier curves showing the cumulative incidence of the primary endpoint according to tertiles at enrolment
(T1: ≤77; T2: 78–115; T3: >116 ng/L).
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Discussion
The main ﬁnding in our study is that patients with HFrEF and
mild or moderate anaemia had markedly increased circulat-
ing levels of the tumour marker proGRP, with a value above
the upper reference limit in 64% of cases. High proGRP levels
were associated with worse HF, as evaluated by clinical and
biochemical indices, and with adverse long-term outcome.
However, proGRP did not add independent prognostic infor-
mation on outcomes after adjustment for clinical and bio-
chemical indices of HF severity.
Levels of proGRP were only mildly elevated in our small co-
hort of HF patients compared with healthy controls, but the
more pronounced differences in the most severely affected
patients (i.e. NYHA IV) and the association with outcome in
the top tertile of proGRP encouraged us to evaluate proGRP
in a larger HF population. ProGRP levels were markedly ele-
vated in a large cohort of HF patients with anaemia from
the RED-HF trial. To the best of our knowledge, these obser-
vations are the ﬁrst reports of proGRP in HF patients. Ele-
vated circulating levels of tumour markers are not
uncommon in HF, although the exact mechanism for their el-
evation is unclear and may vary depending on the marker. In-
creased levels of CA-125 and HE4 in HF and association with
clinical severity and adverse outcome10 have been suggested
to reﬂect congestion17 and immune activation,11,18 whereas
increased CgA levels in HF, a marker of neuroendocrine dif-
ferentiation, have been suggested to reﬂect overall neuroen-
docrine activity.4 We found that proGRP levels were
associated with multiple clinical and biochemical markers of
HF severity with kidney function and NT-proBNP as the stron-
gest determinants in both cohorts. In addition, galectin-3,
which we have previously reported in the clinical HF cohort,15
was a strong determinant of proGRP.
Expression of both GRP mRNA and proGRP protein has
been detected in experimental models and human kidney cell
lines.19 Furthermore, elevated proGRP levels correlate with
the severity of renal failure in several studies with a decrease
following haemodialysis indicating renal metabolism and/or
excretion, limiting its use as a prognostic marker in patients
with reduced renal function.20,21 As for cardiac tissues, we
found no reports on proGRP expression. However, protein
Table 3 Interaction between baseline levels of proGRP and BMI on
outcomes in the RED-HF study
Variables HR P
All-cause mortality or ﬁrst hospitalization for worsening HF
ProGRP 1.14 (0.82–1.58) 0.444
BMI 0.99 (0.98–1.00) 0.157
ProGRP × BMI 1.00 (0.99–1.02) 0.471
CV mortality or ﬁrst hospitalization for worsening HF
ProGRP 1.13 (0.80–1.59) 0.500
BMI 0.99 (0.98–1.01) 0.324
ProGRP × BMI 1.00 (0.99–1.02) 0.474
All-cause mortality
ProGRP 1.10 (0.77–1.59) 0.600
BMI 0.97 (0.96–0.99) <0.001
ProGRP × BMI 1.01 (0.99–1.02) 0.36
CV mortality
ProGRP 1.09 (0.73–1.63) 0.677
BMI 0.97 (0.95–0.99) <0.001
ProGRP × BMI 1.01 (0.99–1.02) 0.380
BMI, body mass index; CV, cardiovascular; HF, heart failure; HR,
hazard ratio; proGRP, pro-gastrin-releasing peptide.
Table 2 Association between baseline levels of proGRP and outcomes in the RED-HF study
UNI Step 1 Step 2
All-cause mortality or ﬁrst hospitalization for worsening heart failure
T2 1.52 (1.27–1.82) 1.19 (0.99–1.44) 0.93 (0.77–1.13)
T3 1.91 (1.60–2.28) 1.26 (1.03–1.54) 1.00 (0.81–1.22)
Continuous 1.35 (1.24–1.47) 1.11 (1.00–1.23) 0.97 (0.87–1.08)
P-trend/P-cont* <0.001/<0.001 0.070/0.042 0.667/0.604
Cardiovascular mortality or ﬁrst hospitalization for worsening heart failure
T2 1.49 (1.23–1.81) 1.17 (0.96–1.43) 0.92 (0.75–1.13)
T3 1.86 (1.54–2.24) 1.21 (0.98–1.50) 0.96 (0.78–1.19)
Continuous 1.34 (1.23–1.47) 1.10 (0.99–1.22) 0.96 (0.86–1.08)
P-trend/P-cont* <0.001/<0.001 0.169/0.087 0.715/0.490
All-cause mortality
T2 1.66 (1.36–2.05) 1.29 (1.04–1.60) 1.05 (0.84–1.30)
T3 2.06 (1.69–2.52) 1.33 (1.06–1.67) 1.07 (0.85–1.35)
Continuous 1.40 (1.28–1.54) 1.15 (1.03–1.29) 1.02 (0.90–1.15)
P-trend/P-cont* <0.001/<0.001 0.029/0.016 0.839/0.756
Cardiovascular Mortality
T2 1.62 (1.29–2.02) 1.25 (0.99–1.57) 1.01 (0.80–1.28)
T3 1.99 (1.60–2.48) 1.27 (0.99–1.63) 1.02 (0.79–1.30)
Continuous 1.39 (1.26–1.54) 1.14 (1.01–1.30) 1.01 (0.88–1.15)
P-trend/P-cont* <0.001/<0.001 0.111/0.039 0.993/0.934
proGRP, pro-gastrin-releasing peptide.
Hazard ratios and 95% conﬁdence interval are shown for proGRP Tertiles 2 and 3 compared with Tertile 1 and for proGRP as a continuous
(log) variable in univariate (UNI) analysis, when adjusted for clinical and biochemical variables (Step 1), and lastly for C-reactive protein,
troponin T, and N terminal pro brain natriuretic peptide (Step 2).
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levels of the GRP-homologue bombesin have been detected
in cardiac tissue from rats22 and have also been shown to reg-
ulate blood pressure through peripheral α-adrenergic recep-
tors.6 ProGRP levels in patients from the RED-HF trial were
moderately associated with features characterizing anaemia
in HF such as lower haemoglobin and transferrin saturation
but were not correlated with inﬂammation as reﬂected by
C-reactive protein or white blood cell. However, although
C-reactive protein is a reliable marker of general systemic in-
ﬂammation, it does not necessarily reﬂect local and more
speciﬁc inﬂammatory processes in a complex disease such
as HF. Our ﬁnding that proGRP correlated strongly with
galectin-3, a macrophage activation marker that is involved
in the progression of HF through promotion of myocardial ﬁ-
brosis and inﬂammation,23,24 may suggest a role for proGRP
in myocardial remodelling. We found no previous studies
evaluating a link between proGRP and ﬁbrosis; however,
bombesin has been shown to promote pulmonary ﬁbrosis.25
Also, antagonism of the GRP receptor reduced mortality rates
by limiting inﬂammatory inﬁltration in a sepsis model and at-
tenuated TLR-4 signalling and the release of inﬂammatory cy-
tokines from activated macrophages.26,27 Taken together, as
GRP is an important regulator of catecholamine secretion,7
which may increase production of BNP,28 proGRP levels in
HF seem to reﬂect neurohormonal activation, worsening kid-
ney function, and myocardial remodelling. However, we can-
not exclude the possibility that the failing myocardium itself
could, at least in part, contribute to the elevated levels of
proGRP in HF patients.
In multivariable analysis adjusting for pre-speciﬁed clinical
variables, proGRP levels were still associated with some ad-
verse outcomes. However, when NT-proBNP, C-reactive pro-
tein, and TnT were added to the model, proGRP was not
signiﬁcantly associated with any of the outcomes. The strong
association between proGRP and other markers for HF sever-
ity and in particular NT-proBNP in the RED-HF cohort could
explain the marked attenuation of risk in patients with high
proGRP levels upon multivariable adjustment for NT-proBNP,
C-reactive protein, and TnT. The inverse association between
BMI and all-cause and CV deaths in our study supports the
well-established inverse association between BMI and risk
of mortality in HFrEF.29 While BMI and proGRP were inversely
correlated in our patients, no interaction between BMI and
proGRP was detected. Finally, no association between change
in proGRP levels during 6 month follow-up and outcome was
observed. Thus, the clinical usefulness of proGRP as a predic-
tor of long-term outcome is likely to be limited.
In conclusion, the neuropeptide proGRP is increased in HF,
in particular in patients with severe clinical disease and poor
renal function. Whereas our data further support an associa-
tion between tumour markers and HF, proGRP adds little as a
prognostic marker on top of conventional CV risk factors
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